Business Wire

CSC Announces Launch of CSC Security Center

Share

CSC Security Center℠ is a first-of-its-kind online interface, designed to expose security blind spots that make vital online brand assets susceptible to cyber crime. Powered by advanced analytics built by CSC® to identify these risks, companies can take quick action to reduce real-world online threats that compromise web presence, customer data, and critical business functions, such as email.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180724005612/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CSC Security Center (Photo: Business Wire)

CSC has been a leader in supporting brand owners for the past two decades—providing corporate domain name management, digital brand strategy, and administration of domain-related products such as domain name system (DNS), secure sockets layer (SSL) certificates, and new generic top-level domains (gTLDs).

“We understand the seemingly impossible job our clients face keeping their companies and brand assets safeguarded against internal and external security threats, and that the ability to conduct business is their top priority,” says CSC Digital Brand Services General Manager Mark Calandra. “Despite prevalent cyber crime, businesses often overlook the security of domain names, DNS, and SSL certificates. CSC Security Center gives our clients insight into—and easy control of—these important components of their online brands.”

CSC Security Center uses advanced proprietary algorithms to identify business-critical domains and ensure they are protected. This includes making sure domains are locked at the registry and registrar levels to prevent unauthorized changes, reviewing users and access levels for correct permissions, and checking that the right DNS hosting and SSL certificates are implemented in CSC client portfolios.

“The domain industry is no stranger to hackers and cyber criminals taking control and modifying or redirecting domain names, putting a company’s business, revenue, and reputation at risk,” says Calandra. “CSC Security Center is designed to not only tell our clients if they have a problem, but what they need to do to fix it. Our goal is to help our clients avoid these situations by providing them a single view into all these areas of risk.”

CSC partners with its clients to help tackle their most complex online brand challenges. CSC thrives on providing solutions that allow their clients to perform at their best.

“We are excited to introduce CSC Security Center to the market,” says Calandra. “It’s an essential companies won’t know they need until they see it. We believe this will redefine what domain management means.”

To find out more about how you can protect your blind spots and implement CSC Security Center, visit the website.

About CSC

CSC is a world leader of digital brand services headquartered in Wilmington, Delaware, and operating from offices throughout the U.S., Canada, Europe, and the Asia-Pacific region.

CSC helps businesses thrive online. We help effectively manage, promote, and secure our clients’ valuable brand assets against the threats of the online world. Leading companies around the world choose us to be their trusted partner, including more than 65% of the Interbrand® 100 Best Global Brands. Leveraging state-of-the-art technology, Digital Brand Services delivers outstanding outcomes through our unique account management structure. With our expert, dedicated team, you’ll have a daily point of contact to ensure your brand has the strength it needs to succeed in the 21st century. We help consolidate and secure, monitor and enforce, then optimize and promote your brands in order to maximize your digital presence, secure your digital intellectual property, and reduce costs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CSC
Laura Crozier
Public Relations Manager, USA
302-636-5401 x. 65526
Laura.Crozier@cscglobal.com
CSC News Room
or
Letitia Thian
Marketing Manager, APAC
+65 6709 0104, x. 80104
Letitia.Thian@cscglobal.com
or
Marie Le Maitre
Marketing Manager, EMEA
+44 (0)20 75132324
Marie.LeMaitre@cscglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye